GenapSys and Twist Bioscience team up to advance sequencing

The company aim to bring NGS target enrichment and library preparation to ‘world’s most accessible highly accurate sequencer’

Register for free to listen to this article
Listen with Speechify
REDWOOD CITY, Calif. & SOUTH SAN FRANCISCO, Calif.—GenapSys Inc. was already quite proud of its technology, calling itself “the company behind the world’s first highly accurate, affordable and portable gene sequencer,” but now it seeks to up the ante a bit by entering into an original equipment manufacturer (OEM) partnership with Twist Bioscience, a company that provides clients with high-quality synthetic DNA.
On Feb. 24, the two companies announced that they will bring a broad and comprehensive range of target enrichment and library preparation tools for next-generation sequencing (NGS) to GenapSys’ high-accuracy sequencer offering. This is expected to enable owners of GenapSys’ NGS technology to more easily and effectively conduct research in oncology, whole-exome sequencing, rare diseases, viral outbreaks, drug discovery and more—as well as enabling them to only have to deal with a single vendor for this kind of work.
“This OEM collaboration with GenapSys provides an ideal option for research laboratories, government organizations and sequencing providers, including healthcare facilities, to get access to our assays on GenapSys distributed sequencers,” said Dr. Emily M. Leproust, CEO and co-founder of Twist Bioscience. “We believe in bringing best-in-class solutions together to offer customers optimal workflows for their needs, and with the distributed nature of the GenapSys high accuracy and affordable sequencer, there is the potential for wider adoption, benefitting a greater number of researchers and clinicians.”
Added Dr. Hesaam Esfandyarpour, founder and CEO of GenapSys: “We’re thrilled to work with an industry leader like Twist Bioscience to give our customers the flexibility and comprehensive capabilities they need from target-enriched, high-quality libraries on our high-accuracy sequencing solution, in a single offering. Through this partnership, GenapSys enables researchers to have access to an efficient, end-to-end sequencing solution with almost limitless applications in life sciences.”
The collaboration with Twist Bioscience will take effect immediately, with GenapSys integrating the new library preparation and target enrichment products starting in the second quarter of this year.
In other news around the same time as this announcement, Twist Bioscience announced that the Twist Targeted Methylation Sequencing Solution—used to study methylation pattern changes in a wide range of research fields including cancer, epigenetics and non-invasive prenatal testing—is now available for early access customers. In addition, the company announced the launch of its Twist Comprehensive Exome Panel, an NGS target enrichment solution that reportedly includes more than 99 percent of protein coding genes.
“Our NGS products continue to meet and exceed our customers’ expectations; building on our high-quality DNA that leads to uniform capture of the regions of interest results in more efficient sequencing, and ultimately better research,” commented Leproust.

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

DDN July 2024 Magazine Issue

Latest Issue  

• Volume 20 • Issue 4 • July 2024

July 2024

July 2024 Issue